SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
This Quarter Return
+32.15%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$901M
AUM Growth
+$901M
(-9.2%)
Cap. Flow
-$248M
Cap. Flow
% of AUM
-27.47%
Top 10 Holdings %
Top 10 Hldgs %
45.07%
Holding
107
New
16
Increased
16
Reduced
34
Closed
33
Top Buys
| 1 |
HCA Healthcare
HCA
|
$27.5M |
| 2 |
IDEAYA Biosciences
IDYA
|
$20.1M |
| 3 |
Penumbra
PEN
|
$20M |
| 4 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$18.4M |
| 5 |
GSK
GSK
|
$12.4M |
Top Sells
| 1 |
TG Therapeutics
TGTX
|
$38.2M |
| 2 |
Arcellx
ACLX
|
$26.9M |
| 3 |
Insulet
PODD
|
$20.4M |
| 4 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$20.3M |
| 5 |
Evolus
EOLS
|
$19M |
Sector Composition
| 1 | Healthcare | 99.95% |
| 2 | Consumer Staples | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Teva Pharmaceuticals
TEVA
$21.1B
| $58.1M | 6.45% | 5,564,440 -487,724 | -8% | -$5.09M |
|
2
United Therapeutics
UTHR
$13.8B
| $54.9M | 6.09% | 249,449 -37,716 | -13% | -$8.29M |
|
|
3
GSK
GSK
$79.9B
| $47.4M | 5.26% | 1,278,540 +335,540 | +36% | +$12.4M |
|
|
RYZB
4
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| $46.4M | 5.15% | 746,622 +295,459 | +65% | +$18.4M |
|
|
EDAP
5
EDAP TMS
EDAP
$84.5M
| $38.2M | 4.23% | 7,226,341 +969,557 | +15% | +$5.12M |
|
6
Organogenesis Holdings
ORGO
$653M
| $36.7M | 4.07% | 8,963,000 -3,333,163 | -27% | -$13.6M |
|
7
Humana
HUM
$36.5B
| $33.7M | 3.74% | 73,706 +4,904 | +7% | +$2.25M |
|
8
Celcuity
CELC
$2.17B
| $31.8M | 3.52% | 2,179,481 +122,997 | +6% | +$1.79M |
|
9
iRadimed
IRMD
$921M
| $30.5M | 3.39% | 643,206 +15,000 | +2% | +$712K |
|
10
ESSA Pharma
EPIX
$11.4M
| $28.6M | 3.17% | 4,327,622 +40,528 | +0.9% | +$267K |
|
11
Surmodics
SRDX
$487M
| $28.1M | 3.11% | 771,700 -459,162 | -37% | -$16.7M |
|
|
12
HCA Healthcare
HCA
$94.5B
| $27.5M | 3.05% | +101,500 | New | +$27.5M |
|
13
Vaxcyte
PCVX
$4B
| $26.1M | 2.89% | 415,450 -84,200 | -17% | -$5.29M |
|
14
Neuropace
NPCE
$303M
| $25.1M | 2.78% | 2,433,168 -33,037 | -1% | -$341K |
|
15
Nuvalent
NUVL
$5.52B
| $23.8M | 2.64% | 322,888 +168,472 | +109% | +$12.4M |
|
|
MREO
16
Mereo BioPharma
MREO
$272M
| $22.6M | 2.51% | 9,777,419 +100,000 | +1% | +$231K |
|
|
17
IDEAYA Biosciences
IDYA
$2.15B
| $20.1M | 2.23% | +564,700 | New | +$20.1M |
|
|
18
Penumbra
PEN
$10.6B
| $20M | 2.22% | +79,400 | New | +$20M |
|
19
Axogen
AXGN
$743M
| $17.7M | 1.97% | 2,595,815 -1,190,014 | -31% | -$8.13M |
|
20
AtriCure
ATRC
$1.84B
| $14M | 1.55% | 392,195 +86,195 | +28% | +$3.08M |
|
21
Rigel Pharmaceuticals
RIGL
$697M
| $13.7M | 1.52% | 9,442,579 -5,360,436 | -36% | -$7.77M |
|
22
Immunovant
IMVT
$2.56B
| $13.4M | 1.48% | 317,050 -82,549 | -21% | -$3.48M |
|
23
Treace Medical Concepts
TMCI
$464M
| $12.9M | 1.43% | 1,014,005 -893,818 | -47% | -$11.4M |
|
24
Smith & Nephew
SNN
$16.3B
| $12.8M | 1.42% | 470,198 -183,702 | -28% | -$5.01M |
|
25
Verastem
VSTM
$569M
| $11.6M | 1.29% | 1,425,634 +78,265 | +6% | +$637K |
|